SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: Amgen's office in Massachusetts/iStock,
Mergers & acquisitions
Amgen Makes up to $840M Cancer Play With Dark Blue Takeover
The acquisition is centered on Dark Blue Therapeutics’ small-molecule degrader of the MLLT1 and MLLT3 proteins, which is being tested for acute myeloid leukemia.
January 7, 2026
 · 
1 min read
 · 
Tristan Manalac
Podcast
Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus
Novo Nordisk follows Christmas oral Wegovy approval with quick launch; Eli Lilly is headed for $94.3 billion in annual revenue by 2027, analysts predict; nine more pharmas strike Most Favored Nation deals but half remain unsigned; experts call for stability and rare disease action at FDA, and all eyes are on M&A ahead of the J.P. Morgan Healthcare conference next week.
January 7, 2026
 · 
2 min read
 · 
Heather McKenzie
Two individuals shake hands in front of advanced laboratory equipment, symbolizing a partnership or agreement in the pharmaceutical industry.
Insights
Biotech Investors Bet on a 2026 Rebound as Deal Activity Accelerates
After a prolonged funding chill, investors say 2026 is shaping up for continued dealmaking and diversified bets beyond oncology and immunology.
January 7, 2026
 · 
3 min read
 · 
Jennifer Smith-Parker
NextGen
BioSpace’s NextGen Class of 2026 Attracts Big Bucks From Tight Wallets
From biotech veterans to embattled modalities to a new wave of RNAi therapeutics, BioSpace’s NextGen Class of 2026 emerged during a tough fundraising environment in 2025. Check out the 15 battle-tested companies that caught our eye.
January 7, 2026
 · 
2 min read
 · 
Annalee Armstrong
Neuroscience
Deep Dive: Huntington’s at a Crossroads
Recent breakthroughs and three decades of progress in treating Huntington’s disease
January 6, 2026
 · 
2 min read
 · 
Heather McKenzie
Team work with speech bubble connect. concept of Conversation or communication for success, meeting discussion to get answer or solution, working together, partnership or collaboration
Weight Loss
Arrowhead Enters Obesity Chat by Doubling Tirzepatide’s Weight Loss in Combo Study
Arrowhead heralded the results as proof of concept that inhibiting the Activin E pathway can improve body composition and enhance weight loss as compared to tirzepatide alone, particularly in patients with type 2 diabetes.
January 6, 2026
 · 
3 min read
 · 
Annalee Armstrong
A handshake of businessmen. Modern design with a positive context. Concept of help, support, and agreement between businessmen. Modern art collage, trendy magazine style.
Obesity
Lilly Doubles Down With Nimbus, Paying $55M for Preclinical Obesity Drug
Eli Lilly kicked off a pivotal 2026 campaign with a multi-year collaboration with current partner Nimbus Therapeutics worth a potential $1.3 billion for a preclinical obesity therapeutic. The deal follows a 2022 partnership struck by the companies to target the AMPK protein in cardiometabolic diseases.
January 6, 2026
 · 
2 min read
 · 
Heather McKenzie
3D Illustration of unlucky business man under rain, surreal concept
Vaccines
Vaccine Investors Keep Their Heads Down as Trump Cuts Shot Schedule
The US dramatically altered its recommendations for a series of vaccines, which drive billion-dollar earnings for giants like Merck and Pfizer.
January 6, 2026
 · 
3 min read
 · 
Dan Samorodnitsky
Gentilly, France, March 21, 2021: Exterior view of the Sanofi headquarters building. Sanofi is a French multinational company specializing in the health sector
Multiple sclerosis
Sanofi’s MS Drug Tripped Up by Toxicities, Unclear Benefit, Rejection Letter Reveals
Last month, the FDA declined to approve Sanofi’s tolebrutinib for a specific form of multiple sclerosis. In a recently published complete response letter, the agency detailed its reasoning behind the rejection.
January 6, 2026
 · 
3 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS